562
BRITISH MEDICAL JOURNAL
Whether the presence of cotton wool spots can be
used to predict the development of either cytomegalovirus retinitis or other cytomegalovirus
disease later in the patient's illness has yet to be
determined.
We thank Mr R Marsh for his evaluation of these
patients.
J M PARKIN
SUSAN M FORSTER
MoIRA THOMSON
A J PINCHING
D J JEFFRIES
tDepartment of Immunology and
Division of Virology,
St Mary's Hospital Medical School,
London W2 1PG, and
Syntex Research, Maidenhead
I Humphey RC, Weber JN, Marsh RJ. Theophthalmic findings of
a group of ambulatory patients infected by humaui T cell
lymphotropic virus type III (HTLV III)-a prospective study.
BrJ Ophuhalmol (in press).
Informed consent
SIR,-I hope Jonathan Glover's leading article (19
July, p 157) stimulates the debate he rightly
proposes about exceptions to the rule that no
patient should participate in research without
informed consent. The rule raises particular problems with the newborn. ' Some babies admitted to
neonatal nurseries are at risk of lethal illness and
damaging complications. If death'and handicap are
to be reduced further it is essential that research
continues rapidly, and with the support and
approval of the community.
In neonatal medicine, as elsewhere, randomised
trials of adequate size and design are the most
reliable way of comparing the safety and value of
treatments.' Ethics committees usually approve
proposals for neonatal trials if they are relevant,
scientifically valid, and involve the parents' permission. When standard or alternative treatment
of a sick baby must begin very soon after birth,
however, it may be impossible first to obtain the
meaningful permission of the parents. They may
be in a state of shock or in another hospital, or the
mother may herself be ill or recovering from an
anaesthetic. Perhaps information should be given
about the small risk of a particular illness in
newborn infants and parents' attitudes to a trial
sought earlier in pregnancy. Evidence that this
could be done without unjustifiable anxiety and
prohibitive cost would be extremely useful. Meanwhile we must sometimes choose either to exclude
infants like this from trials or enter them without
priorspecific permission.
If such infants are excluded from trials advances
in certain critical neonatal illnesses will inevitably
be slowed. If such infants are to be included
doctors should have the support of the community.
This is partly expressed through local ethics
committees, which increasingly include lay members. Most ethics committees-will give doctors this
support if an important trial is likely to fail without
it. Doctors in their turn should always examine
their motives for pleading an exception to the
obligation of prior informed consent. Withholding
information from parents is sometimes a form of
overprotection and can look very much like deceit.
I hope the debate is conducted sensitively.
Those who fuel headlines accusing paediatricians
of "experimenting on babies without their parents'
permission" could very well polarise it beyond
recall. If this destroys the trust on which neonatal
research depends the consequences could be severe.
-
SIR,-Jonathan Glover's leading article (19 July,
p 157) raises important issues on the subject of
informed consent in MRC trials. I accept the
principle that all patients have a right to be
informed and should participate in trials voluntarily.
The example quoted in the leading article seems
fairly straightforward. Cancer of the prostate
is generally not an immediately life threatening
disease, and there is no rush to institute treatment.
The two forms of treatment being compared are
radically different so patients should be made
aware of the alternatives and should be asked to
provide informed consent.
However, consideration of the MRC trial for
treatment of acute leukaemia is much more difficult. Patients with acute leukaemia have an illness
which may prove fatal in the short term and the
treatments being compared are extremely similar,
precisely the same drugs for remission-induction
being given to the patients but simply in a different
dose schedule. Most patients have their own
preconceived ideas of leukaemia and the initial
impact of the diagnosis can be devastating. The
hazards of toxic chemotherapy programmes then
have to be faced. Do we have to inflict further
trauma by raising genuine doubts about the effectiveness of treatment? Whose best interests are
being served then?
Jonathan Glover implies that the difficulty in
spelling out a grim prognosis is used as an excuse
for violating the informed consent requirement. A
grim prognosis can still be spelt out, particularly
with acute leukaemia, and informed consent obtained, but I cannot agree that this is the most
appropriate time to raise doubts in a patient's mind
by references to "research." Undoubtedly, better
patient education is required, but few of us can
deny that there are patients for whom the mention
of "research" immediately raises fears of being
used as a "guinea pig." This is a difficult issue to
tackle at the best of times with a chronic and
relatively benign illness but becomes particularly
difficult in the context of malignant disease.
I also fail to understand the preoccupation with
consent forms. A signature on a consent form does
not make a patient any better informed and is
positively disadvantageous. The standard surgical
consent form is seen as an absolving of responsibility on the part of the doctor should complications
ensue and surely this is not the impression we want
to convey before treating someone with malignant
disease.
Patients should be informed that there are
alternative forms of treatment being compared for
the disease, but the problem arises with the use of
words such as "trial" or "research". It should be
made clear to all patients with malignancy that the
treatment they are to receive is still the best
currently available. Clear rules are required for the
protection- of- patients but they also have to be
flexible rules. I could not agree more that "the
excep5ions need fuller debate."
J A MuR.RAY
Department of Haematology,
Selly Oak Hospital,
Birmingham B29 6JD
VOLUME 293
30 AUGUST 1986
information? What are the effects of doctors'
own emotions on the way they communicate
information to their patients? What are the differential effects of risk disclosure on medical outcome?
Until we can properly address these questions
blanket policies on informed consent seem less and
less valid or realistic. A rigid policy in favour of
"full disclosure" (if indeed there is such a thing)
clearly violates the needs of patients who do not
want such information. Yet to adopt a flexible
approach means that doctors must learn to live
with their own uncertainties and be prepared to
spend more time exploring the needs of individual
patients.
As patients we must also recognise that there are
costs (as well as benefits) of "fully informed
consent"-namely, fear and uncertainty. The
costs to both patient and doctor could be minimised
by improving the quality of the communication
between them. This aspect is expressed admirably
by Brewin. ' There is a substantial body of empirical
evidence (King JB, unpublished paper for the
Central Oxford Research Ethics Committee,
Oxfordshire Health Authority) which could help
to move the informed consent debate towards a
greater real consideration of what is best for the
patient.
JENNIFER KING
Bristol BS8 2TS
1 Brewin T. Truth, trust and paternalism. Lancet 1985;ii:490-2.
Randomised trial of preterm breech
delivery
SIR,-Mr P B Terry and Dr D J Lloyd (12 July,
p 138) draw attention to the need for multicentre
collaboration if a randomised controlled trial of
elective versus selective use of caesarean section for
delivery of preterm infants presenting by the
breech is to be of sufficient size. They might
also have pointed out that the obstacles to such
studies have been successfully negotiated in other
specialties. For example, on the day that their
letter was published a trial (ISIS-1) was reported
that involved over 1600 patients with suspected
myocardial infarction recruited from 245 collaborating coronary care units. '
As long ago as 1981 the need for a trial of elective
caesarean section for preterm breech delivery was
recognised2 3; this call was reiterated last year by a
study group of the Royal College of Obstetricians
and Gynaecologists.4 A protocol for a European
trial, prepared by Professor Piet Treffers from
Amsterdam, was later endorsed by the Royal
College of Obstetricians and Gynaecologists.
Furthermore, the issue of preterm breech delivery
was a feature of the inaugural meeting of the
European Association of Gynaecologists and
Obstetricians, which took place in London this
summer.
The intentions are good, but actions speak
louder than words. When will obstetricians begin
to take concerted action, similar to that of the
many cardiologists who collaborated in the ISIS-1
trial, to address this and other important andlongstanding questions that demand collaboration
in multicentre trials?
ADRIAN GRANT
National Perinatal Epidemiology Unit,
Radcliffe Infirmary,
SIR,-Jonathan Glover clearly highlights several
important issues on inforned consent arising from
the debate over the MRC's policies on clinical
trials. In the tendency to focus on legal and ethical
aspects Dr Glover and many others concerned in
the debate about informed consent typically over- Oxford OX2 6HE
look some fundamental empirica questions.
Study of Infarct Survival Collaborative
~~WILLIAM TAitNOW-MoiwI For example, do patients want to knlow about 1 FirstGroup.International
Randomised trial of inravenous atenolol among 16027
casea of suspected acute myocardial infarction: ISIS-i. Lances
potential treatment risks? How does such risk
Oxford
1 Dswson J. Randomsiaed trials and informed consent in neonatal
medicine. BrMcd3' 1986;292:1373-4.
2 Hetcheimer A, Zentler-Munro, Winn D. Therapeutic trials and
society. L:ondon: Consumers' Association, 1986.
I986;ii:57-66.
disclosure affect their ability to make an "inP. Mode of delivery and aurvival in babies weighing less
formed" decision?Howdopain, fear, and hospirali- 2 Crowley
than 2000g at birth. BrMcd3' 1981;282:71-2.
sation affect patients' recall and comprehension of 3 Smith ML, spencer SA, Hull D. Modeof delivery and survival in